Cartesian Therapeutics, Inc.
RNAC · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $39 | $26 | $111 | $85 |
| % Growth | 49.6% | -76.5% | 30.2% | – |
| Cost of Goods Sold | $0 | $0 | $2 | $0 |
| Gross Profit | $39 | $26 | $109 | $85 |
| % Margin | 100% | 100% | 98.2% | 100% |
| R&D Expenses | $45 | $71 | $72 | $69 |
| G&A Expenses | $30 | $40 | $24 | $21 |
| SG&A Expenses | $30 | $40 | $24 | $21 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $8 | $1 | -$2 | $0 |
| Operating Expenses | $83 | $112 | $94 | $90 |
| Operating Income | -$44 | -$86 | $15 | -$5 |
| % Margin | -112.8% | -332.3% | 13.1% | -5.4% |
| Other Income/Exp. Net | -$33 | -$152 | $20 | -$5 |
| Pre-Tax Income | -$77 | -$239 | $35 | -$10 |
| Tax Expense | $0 | -$19 | -$1 | $16 |
| Net Income | -$77 | -$220 | $35 | -$26 |
| % Margin | -199% | -844.9% | 31.9% | -30.2% |
| EPS | -2.99 | -49.76 | 7.33 | -6.74 |
| % Growth | 94% | -778.9% | 208.8% | – |
| EPS Diluted | -3.29 | -49.76 | 3 | -6.6 |
| Weighted Avg Shares Out | 26 | 5 | 4 | 3 |
| Weighted Avg Shares Out Dil | 24 | 5 | 4 | 3 |
| Supplemental Information | – | – | – | – |
| Interest Income | $7 | $5 | $0 | $0 |
| Interest Expense | $0 | $3 | $3 | $3 |
| Depreciation & Amortization | $1 | $1 | $2 | $2 |
| EBITDA | -$76 | -$235 | $40 | -$5 |
| % Margin | -195.3% | -903.8% | 36% | -6.1% |